The combination of bortezomib, melphalan, dexamethasone and intermittent thalidomide is an effective regimen for relapsed/refractory myeloma and is associated with improvement of abnormal bone metabolism and angiogenesis
September 6th, 2008 by 
admin The compounding of bortezomib, melphalan, Hexadrol and intermittent thalidomide is an trenchant program for relapsed/refractory myeloma and is related with transformation of deviant pearl metastasis and angiogenesis
Leukemia front online publication, Sept 4, 2008. doi:10.1038/leu.2008.235
Authors: E Terpos, E Kastritis, M Roussou, D Heath, D Christoulas, N Anagnostopoulos, E Eleftherakis-Papaiakovou, K Tsionos, P Croucher
& M A Dimopoulos (Source: Leukemia)
Posted in Cancer | 